Stanford-Founded Startup Raises $11.6M for Noninvasive Wearable Hormone Monitor

Jenny Duan, a 22-year-old Stanford University graduate, spent months diligently logging her menstrual cycle into a smartphone app, hoping the data would eventually yield actionable insights. Instead, she found that the app's calendar-based predictions consistently missed the mark, failing to capture the reality of her irregular cycles. That frustration has now materialized into a heavily funded company. Clair Health, co-founded by Duan and fellow Stanford alum Abhinav Agarwal, recently emerged from stealth to announce an $11.6 million seed round aimed at launching the first noninvasive, continuous hormone-monitoring wearable.[1][2]

The funding round, led by Khosla Ventures with participation from a16z speedrun and 23andMe co-founder Anne Wojcicki, validates a surging market demand for advanced women's health technology. The startup's flagship device, which features a rose-gold housing and soft band designed to resemble jewelry rather than a bulky fitness tracker, is slated for a November 2026 commercial launch. Even before hitting the market, Clair Health reports that more than 25,000 people have joined its waitlist, signaling widespread consumer appetite for better reproductive health data.[1]

Unlike traditional hormone tracking methods—which rely on invasive blood draws, inconvenient saliva swabs, or daily urine test strips—Clair's wearable does not measure chemical hormones directly. Instead, it utilizes "physiological inference." The wrist-worn device is packed with 10 distinct biosensors that continuously monitor a wide array of biometric signals, including skin temperature, resting heart rate, heart rate variability (HRV), breathing rate, and electrodermal activity.

These continuous multimodal signals are fed into a proprietary artificial intelligence model trained on paired wearable sensor data and clinical-grade hormone measurements. By analyzing how the body's cardiovascular and thermoregulatory systems shift, the algorithm estimates real-time fluctuations in four key reproductive hormones: estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Because hormones act as one of the body's earliest signaling systems, their systemic effects can be reliably decoded by advanced machine learning.[2]

The technology aims to address a massive, historical data gap in medical research. For decades, women have been systematically underrepresented in clinical trials, resulting in a healthcare system that often treats male physiology as the default baseline. This lack of foundational research means that many women navigate their reproductive years, from their first period through perimenopause, with fragmented and often dismissive medical guidance regarding their hormonal health.

Furthermore, standard consumer fitness wearables often fail to account for the profound physiological variability introduced by the menstrual cycle. While popular devices like the Oura Ring or Whoop can broadly track cycle phases based on basal body temperature shifts, they do not isolate specific hormone concentrations. Clair is attempting to bridge this gap by providing the granular hormonal context that directly influences a woman's daily energy levels, metabolic rate, and athletic recovery.[3]

To prove its algorithmic approach works, Clair Health conducted rigorous prototype testing designed to capture a diverse cross-section of female physiology. The initial study included more than 40 women and tracked 127 complete menstrual cycles, generating over 5,000 days of continuous biometric data. The participant pool was specifically structured to include representation across different ages, body mass index (BMI) ranges, cycle types, and skin tones, ensuring the optical sensors worked accurately across demographics.[2]

The results of this foundational study demonstrated a 94.1% overall accuracy rate in classifying cycle phases. The system achieved 96% sensitivity during the menstrual phase, 93% in the ovulatory phase, and 94% in the luteal phase, alongside an 87% success rate in detecting the critical LH surge that precedes ovulation. Crucially, the startup validated its predictions against actual clinical-grade hormone assays rather than relying on self-reported calendar dates, which research has shown can be inaccurate in up to half of all phase assignments.[2]

In the current political and legal landscape surrounding reproductive rights, data privacy has become a paramount concern for femtech companies. To address these fears, Clair Health designed its software architecture so that all data processing occurs locally on the user's smartphone app. By keeping the algorithmic inference on the device rather than transmitting it to external cloud servers, the company aims to strictly limit third-party access to sensitive reproductive health information.

Looking ahead, the startup faces the challenge of proving its clinical efficacy to the broader medical community. While many consumer health wearables operate without strict regulatory oversight, Duan and Agarwal plan to seek formal FDA approval to position Clair as a medically credible diagnostic tool rather than a mere lifestyle product. The company is preparing to launch a formal clinical trial at Stanford Medicine this spring, a critical step toward transitioning women's healthcare from reactive treatments to proactive, personalized management.